United States-based Vividion Therapeutics has collaborated with United States-based Celgene, it was reported yesterday.

The collaboration is aimed at discovering therapies against transformative, first-in-class targets. It is focused on the identification and development of unique small molecules against targets for a range of oncology, inflammatory and neurodegenerative indications. It is aimed at advancing new small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit.

Vividion will receive an upfront payment of USD101m, which includes an equity investment from Celgene. The initial term of the collaboration is four years, with the opportunity for Celgene to extend for another two years for an additional payment. Vividion will lead initial discovery efforts and identification of programs to be included in the collaboration, and Celgene will have the right to opt in on those programs at IND application acceptance.